Dan Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dan Yuan has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Junfeng Shi
Hunan Provincial Key Laboratory of Animal Models and Molecular Medicine, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, School of Biomedical Sciences, Hunan University, Changsha, Hunan 410082, China
15 shared publications Xia Wu
Department of Cardiology, the Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, 411100, China
5 shared publicationsHong Han
Hunan Provincial Key Laboratory of Animal Models and Molecular Medicine State Key Laboratory of Chemo/Bio‐Sensing and Chemometrics School of Biomedical Sciences Hunan University Changsha Hunan China
4 shared publicationsJun Shen
Affiliated Hospital of Hunan University, School of Biomedical Sciences, Hunan University, Changsha, China
4 shared publications- Xia Wu
Department of Cardiology The Central Hospital of Xiangtan (The affiliated Hospital of Hunan University), Hunan University Xiangtan Hunan China
4 shared publications - Hong Han
Affiliated Hospital of Hunan University, School of Biomedical Sciences Hunan University Changsha P. R. China
3 shared publications
Latest Publications
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Membrane-confined self-assembly enables localized bioorthogonal prodrug activation and selective cancer therapy
Bioorthogonal prodrug activation offers a promising approach for site-specific drug release, significantly reducing the systemic toxicity associated with conventional chemotherapy. However, challenges remain in precisely controlling prodrug activation at the target site while maintaining optimal selectivity, reactivity, and potency. Here, we report a dual-targeting peptide, TzFFY p HH, that integrates on-membrane enzyme-instructed self-assembly (EISA) with bioorthogonal chemistry to enable selective chemotherapy. Exploiting the overexpression of alkaline phosphatase (ALP) and programmed death-ligand 1 (PD-L1) on cancer cells, TzFFY p HH selectively anchors and self-assembles on the cancer cell membrane, enriching tetrazine (Tz) handles that act as bioorthogonal reactors to activate a trans -cyclooctene (TCO)-caged prodrug (TCO-Dox) for precise drug release. Upon topical administration, TzFFY p HH forms a hydrogel at subcutaneous tumor sites, enabling in situ prodrug activation for effective tumor inhibition. Notably, this localized chemotherapy elicits a potent antitumor immune response, which, when combined with anti-programmed death-1 antibody (αPD-1), synergistically potentiates therapeutic outcomes. By coupling supramolecular self-assembly with bioorthogonal reactivity on the cell membrane, this work establishes a chemically programmable platform for spatiotemporally controlled prodrug activation and provides a general strategy for integrating localized chemotherapy with immunotherapy.
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Membrane-confined self-assembly enables localized bioorthogonal prodrug activation and selective cancer therapy
Bioorthogonal prodrug activation offers a promising approach for site-specific drug release, significantly reducing the systemic toxicity associated with conventional chemotherapy. However, challenges remain in precisely controlling prodrug activation at the target site while maintaining optimal selectivity, reactivity, and potency. Here, we report a dual-targeting peptide, TzFFY p HH, that integrates on-membrane enzyme-instructed self-assembly (EISA) with bioorthogonal chemistry to enable selective chemotherapy. Exploiting the overexpression of alkaline phosphatase (ALP) and programmed death-ligand 1 (PD-L1) on cancer cells, TzFFY p HH selectively anchors and self-assembles on the cancer cell membrane, enriching tetrazine (Tz) handles that act as bioorthogonal reactors to activate a trans -cyclooctene (TCO)-caged prodrug (TCO-Dox) for precise drug release. Upon topical administration, TzFFY p HH forms a hydrogel at subcutaneous tumor sites, enabling in situ prodrug activation for effective tumor inhibition. Notably, this localized chemotherapy elicits a potent antitumor immune response, which, when combined with anti-programmed death-1 antibody (αPD-1), synergistically potentiates therapeutic outcomes. By coupling supramolecular self-assembly with bioorthogonal reactivity on the cell membrane, this work establishes a chemically programmable platform for spatiotemporally controlled prodrug activation and provides a general strategy for integrating localized chemotherapy with immunotherapy.
- Open Access
- 30 September 2026
- Published by Wiley in Advanced Science
- p. e78074
Receptor‐Triggered Peptide Self‐Assembly Enables Multivalent Recruitment of Endogenous Antibodies for Cancer Immunotherapy
Monoclonal antibody–based immunotherapies have achieved remarkable clinical success but remain limited by variable patient responses, immune‐related toxicities, and the complexity of antibody production. Antibody‐recruiting molecules (ARMs) offer an alternative strategy by harnessing endogenous antibodies to induce immune‐mediated tumor clearance; however, their therapeutic efficacy is often constrained by insufficient antibody recruitment arising from weak hapten–antibody interactions. Here we report a receptor‐triggered supramolecular assembly strategy that converts monovalent antibody recruiters into multivalent immunotherapeutic platforms directly on cancer cell surfaces. An EGFR‐targeting peptide (GE11) was conjugated with a dinitrophenyl (DNP) hapten and a short self‐assembly motif to afford a monomeric construct that undergoes EGFR‐mediated in situ self‐assembly into fibrillar networks on EGFR‐overexpressing cells. This receptor‐guided supramolecular transformation generates a high‐density multivalent display of haptens on the cell membrane, enabling efficient recruitment of endogenous anti‐DNP antibodies. The resulting assemblies induce potent complement‐dependent cytotoxicity (CDC) against EGFR‐positive cancer cells in vitro and produce significant antitumor efficacy in tumor‐bearing mouse models with minimal systemic toxicity. This work establishes receptor‐mediated peptide self‐assembly as a general supramolecular strategy for transforming monovalent antibody recruiters into multivalent immunotherapeutic platforms, providing a new framework for the design of selective ARMs for cancer immunotherapy.
- 30 September 2026
- Published by Wiley in Advanced Science
- p. e78074
Open AccessReceptor‐Triggered Peptide Self‐Assembly Enables Multivalent Recruitment of Endogenous Antibodies for Cancer Immunotherapy
Monoclonal antibody–based immunotherapies have achieved remarkable clinical success but remain limited by variable patient responses, immune‐related toxicities, and the complexity of antibody production. Antibody‐recruiting molecules (ARMs) offer an alternative strategy by harnessing endogenous antibodies to induce immune‐mediated tumor clearance; however, their therapeutic efficacy is often constrained by insufficient antibody recruitment arising from weak hapten–antibody interactions. Here we report a receptor‐triggered supramolecular assembly strategy that converts monovalent antibody recruiters into multivalent immunotherapeutic platforms directly on cancer cell surfaces. An EGFR‐targeting peptide (GE11) was conjugated with a dinitrophenyl (DNP) hapten and a short self‐assembly motif to afford a monomeric construct that undergoes EGFR‐mediated in situ self‐assembly into fibrillar networks on EGFR‐overexpressing cells. This receptor‐guided supramolecular transformation generates a high‐density multivalent display of haptens on the cell membrane, enabling efficient recruitment of endogenous anti‐DNP antibodies. The resulting assemblies induce potent complement‐dependent cytotoxicity (CDC) against EGFR‐positive cancer cells in vitro and produce significant antitumor efficacy in tumor‐bearing mouse models with minimal systemic toxicity. This work establishes receptor‐mediated peptide self‐assembly as a general supramolecular strategy for transforming monovalent antibody recruiters into multivalent immunotherapeutic platforms, providing a new framework for the design of selective ARMs for cancer immunotherapy.
- Open Access
- 13 September 2026
- Published by Wiley in Advanced Science
- p. e77674
Multifunctional Zinc Glycyrrhizinate‐Integrated Gel for Enhanced Probiotic Delivery and Alleviation of Acute and Spontaneous Colitis
Effective probiotic therapy for colitis is hindered by the harsh gastrointestinal (GI) physiologic and pathologic environment, including acidic pH, bile salts, elevated reactive oxygen species (ROS), mucus depletion, and dysbiosis. To address these challenges, we developed a novel “drug carrier‐integrated” oral probiotic delivery system— L. reuteri @ZGM—based on a zinc glycyrrhizinate microgel (ZGM) derived from the clinical anti‐inflammatory agent Licorzinc. This multifunctional gel encapsulates L. reuteri within a porous network, achieving a 23.08‐fold increase in survival rate under simulated gastric conditions and a 37.22‐fold increase in intestinal colonization in mice compared to unencapsulated bacteria. Beyond protection, ZGM actively scavenges ROS at inflammatory sites, facilitates probiotic adhesion to the mucus layer, and modulates the local microenvironment to favor colonization. In both dextran sulfate sodium (DSS)‐induced colitis and IL‐10‐deficient spontaneous colitis mouse models, L. reuteri @ZGM persistently scavenged ROS, effectively reduced pro‐inflammatory cytokine levels, restored the expression of tight junction‐associated proteins and intestinal barrier function, enhanced probiotic colonization and survival, and reshaped the gut microbiota. These findings establish L. reuteri @ZGM as a potent therapeutic strategy that integrates microenvironment modulation and probiotic delivery—offering a clinically translatable approach to treating inflammatory bowel diseases.
- 13 September 2026
- Published by Wiley in Advanced Science
- p. e77674
Open AccessMultifunctional Zinc Glycyrrhizinate‐Integrated Gel for Enhanced Probiotic Delivery and Alleviation of Acute and Spontaneous Colitis
Effective probiotic therapy for colitis is hindered by the harsh gastrointestinal (GI) physiologic and pathologic environment, including acidic pH, bile salts, elevated reactive oxygen species (ROS), mucus depletion, and dysbiosis. To address these challenges, we developed a novel “drug carrier‐integrated” oral probiotic delivery system— L. reuteri @ZGM—based on a zinc glycyrrhizinate microgel (ZGM) derived from the clinical anti‐inflammatory agent Licorzinc. This multifunctional gel encapsulates L. reuteri within a porous network, achieving a 23.08‐fold increase in survival rate under simulated gastric conditions and a 37.22‐fold increase in intestinal colonization in mice compared to unencapsulated bacteria. Beyond protection, ZGM actively scavenges ROS at inflammatory sites, facilitates probiotic adhesion to the mucus layer, and modulates the local microenvironment to favor colonization. In both dextran sulfate sodium (DSS)‐induced colitis and IL‐10‐deficient spontaneous colitis mouse models, L. reuteri @ZGM persistently scavenged ROS, effectively reduced pro‐inflammatory cytokine levels, restored the expression of tight junction‐associated proteins and intestinal barrier function, enhanced probiotic colonization and survival, and reshaped the gut microbiota. These findings establish L. reuteri @ZGM as a potent therapeutic strategy that integrates microenvironment modulation and probiotic delivery—offering a clinically translatable approach to treating inflammatory bowel diseases.
- 29 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (16) , 7594-7602
Fluorescent-Activating Proteins Manipulate Self-Assembly Peptides Trafficking and Intracellular Distribution
Peptide-based probes and therapeutics are often hindered by lysosomal degradation and stochastic trafficking, which limit their ability to engage specific organelles with precision. Here, we report a self-assembled peptide system incorporating malachite green (MG), engineered to interact with fluorescent-activating proteins (FAPs) for precise regulation of intracellular peptide trafficking and distribution, enabling effective escape from lysosomal processing. By leveraging the specific binding properties of FAPs, our peptide-MG conjugated enables dynamic modulation of subcellular localization, facilitating targeted transport to organelles such as the nucleus, cytoplasm, and outer membrane. Confocal imaging with a fluorescently labeled peptide further revealed that FAP-mediated interactions can reprogram intracellular trafficking pathways. Furthermore, this system affords spatiotemporal control over peptide aggregation and disassembly, highlighting its potential for applications in drug delivery, synthetic biology, and the study of peptide-based cellular processes.
- 29 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (16) , 7594-7602
Fluorescent-Activating Proteins Manipulate Self-Assembly Peptides Trafficking and Intracellular Distribution
Peptide-based probes and therapeutics are often hindered by lysosomal degradation and stochastic trafficking, which limit their ability to engage specific organelles with precision. Here, we report a self-assembled peptide system incorporating malachite green (MG), engineered to interact with fluorescent-activating proteins (FAPs) for precise regulation of intracellular peptide trafficking and distribution, enabling effective escape from lysosomal processing. By leveraging the specific binding properties of FAPs, our peptide-MG conjugated enables dynamic modulation of subcellular localization, facilitating targeted transport to organelles such as the nucleus, cytoplasm, and outer membrane. Confocal imaging with a fluorescently labeled peptide further revealed that FAP-mediated interactions can reprogram intracellular trafficking pathways. Furthermore, this system affords spatiotemporal control over peptide aggregation and disassembly, highlighting its potential for applications in drug delivery, synthetic biology, and the study of peptide-based cellular processes.
- 16 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 12417-12429
Enzyme-Triggered Charge and Conformation Switching for Tumor-Selective Peptide–Drug Conjugates
Functionalizing anticancer drugs with activatable peptides offers a versatile strategy to achieve tumor-selective delivery while minimizing systemic toxicity. Here, we report a γ-glutamyltransferase (GGT)-responsive cell-penetrating peptide (P-EE) generated by γ-glutamyl masking of penetratin for tumor-selective activation in hepatocellular carcinoma. Upon GGT-mediated cleavage, P-EE restores its cationic charge and helical conformation, enabling efficient membrane translocation and selective accumulation in GGT-overexpressing tumor cells. P-EE showed enhanced internalization and approximately 5-fold higher cytotoxic potency in HepG2 cells compared with NHDF normal cells. Covalent conjugation of camptothecin (CPT) to P-EE yielded a peptide-drug conjugate (CPT-P-EE) with greatly improved aqueous solubility, potent antitumor activity, and over 50-fold reduced toxicity to normal cells. In vivo, CPT-P-EE significantly suppressed tumor growth and prolonged survival without inducing systemic toxicity. This study establishes a generalizable enzyme-activatable peptide-drug conjugate platform that integrates conformational switching with targeted delivery, offering a promising direction for precision chemotherapy against GGT-positive malignancies.
- 16 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 12417-12429
Enzyme-Triggered Charge and Conformation Switching for Tumor-Selective Peptide–Drug Conjugates
Functionalizing anticancer drugs with activatable peptides offers a versatile strategy to achieve tumor-selective delivery while minimizing systemic toxicity. Here, we report a γ-glutamyltransferase (GGT)-responsive cell-penetrating peptide (P-EE) generated by γ-glutamyl masking of penetratin for tumor-selective activation in hepatocellular carcinoma. Upon GGT-mediated cleavage, P-EE restores its cationic charge and helical conformation, enabling efficient membrane translocation and selective accumulation in GGT-overexpressing tumor cells. P-EE showed enhanced internalization and approximately 5-fold higher cytotoxic potency in HepG2 cells compared with NHDF normal cells. Covalent conjugation of camptothecin (CPT) to P-EE yielded a peptide-drug conjugate (CPT-P-EE) with greatly improved aqueous solubility, potent antitumor activity, and over 50-fold reduced toxicity to normal cells. In vivo, CPT-P-EE significantly suppressed tumor growth and prolonged survival without inducing systemic toxicity. This study establishes a generalizable enzyme-activatable peptide-drug conjugate platform that integrates conformational switching with targeted delivery, offering a promising direction for precision chemotherapy against GGT-positive malignancies.
- Open Access
- 3 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103099
Redox-responsive peptide folding enables intracellular self-assembly and controlled nucleic acid release
- 3 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103099
Open AccessRedox-responsive peptide folding enables intracellular self-assembly and controlled nucleic acid release
- Open Access
- 11 February 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (2) , 243-253
Enzyme-Activated Self-Assembling Peptides Mimicking Adiponectin Multimers for Nonalcoholic Fatty Liver Disease Therapy
Adiponectin is a multifunctional adipokine that regulates metabolic homeostasis, particularly lipid metabolism, through activation of adiponectin receptors (AdipoRs). Its high molecular weight (HMW) form exhibits the greatest biological activity, yet therapeutic peptides derived from adiponectin typically exist as monomers or aggregates, limiting their efficacy. To mimic the multimeric architecture of adiponectin and enhance peptide efficacy, we developed two alkaline phosphatase (ALP)-activated self-assembling peptides, 1P and 2P, based on a conserved adiponectin sequence (148GKFHCNIPGLYYFAY162). These peptides undergo in situ self-assembly into stable nanofibers in ALP-overexpressing liver tissue, enhancing structural stability and receptor engagement. The assembled peptides effectively bind AdipoRs and reduce lipid accumulation in vitro. In a high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) mouse model, treatment with these peptides led to significant reductions in body weight, blood glucose levels, and hepatic steatosis. Transcriptomic analysis further revealed modulation of key pathways involved in inflammation, lipid synthesis, and metabolism. This study offers a promising strategy for mimicking multimeric adipokine structures and advancing peptide-based therapeutics for NAFLD.
- 11 February 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (2) , 243-253
Open AccessEnzyme-Activated Self-Assembling Peptides Mimicking Adiponectin Multimers for Nonalcoholic Fatty Liver Disease Therapy
Adiponectin is a multifunctional adipokine that regulates metabolic homeostasis, particularly lipid metabolism, through activation of adiponectin receptors (AdipoRs). Its high molecular weight (HMW) form exhibits the greatest biological activity, yet therapeutic peptides derived from adiponectin typically exist as monomers or aggregates, limiting their efficacy. To mimic the multimeric architecture of adiponectin and enhance peptide efficacy, we developed two alkaline phosphatase (ALP)-activated self-assembling peptides, 1P and 2P, based on a conserved adiponectin sequence (148GKFHCNIPGLYYFAY162). These peptides undergo in situ self-assembly into stable nanofibers in ALP-overexpressing liver tissue, enhancing structural stability and receptor engagement. The assembled peptides effectively bind AdipoRs and reduce lipid accumulation in vitro. In a high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) mouse model, treatment with these peptides led to significant reductions in body weight, blood glucose levels, and hepatic steatosis. Transcriptomic analysis further revealed modulation of key pathways involved in inflammation, lipid synthesis, and metabolism. This study offers a promising strategy for mimicking multimeric adipokine structures and advancing peptide-based therapeutics for NAFLD.
- 29 August 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 387, 114176
Enzyme-instructed disassembly of phosphorylated temporin supramolecules enhances doxorubicin synergy for targeted cancer inhibition
- 29 August 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 387, 114176
Enzyme-instructed disassembly of phosphorylated temporin supramolecules enhances doxorubicin synergy for targeted cancer inhibition
- 1 July 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 26 (9) , 5633-5644
Enhanced Intracellular Delivery by Twisted CC-Loop Conformation in Cyclic Cell-Penetrating Peptides
Biological drugs hold great promise for treating various diseases, but their efficacy is often limited by poor cellular uptake. Herein, we introduce cyclic cell-penetrating peptides (CPPs) to enhance the delivery efficiency. Three cyclic peptides with varying ring sizes were designed from a classic amphiphilic CPP via disulfide bond formation. Among them, Y2-13-OX adopted a twisted CC-loop conformation distinct from the typical β-hairpin on negatively charged cell surfaces. This unique structure enhanced membrane penetration, enabling superior delivery compared with linear and other cyclic variants. Y2-13-OX efficiently delivered functional siRNA targeting METTL3, achieving knockdown comparable to that of Lipofectamine 2000. It also transported GFP and plasmids, demonstrating versatility. Computational analysis revealed molecular-level insights into the enhanced interaction between the CC-loop structure and membranes. These findings establish a new CPP conformation that advances therapeutic delivery and opens new avenues for drug transport strategies.
- 1 July 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 26 (9) , 5633-5644
Enhanced Intracellular Delivery by Twisted CC-Loop Conformation in Cyclic Cell-Penetrating Peptides
Biological drugs hold great promise for treating various diseases, but their efficacy is often limited by poor cellular uptake. Herein, we introduce cyclic cell-penetrating peptides (CPPs) to enhance the delivery efficiency. Three cyclic peptides with varying ring sizes were designed from a classic amphiphilic CPP via disulfide bond formation. Among them, Y2-13-OX adopted a twisted CC-loop conformation distinct from the typical β-hairpin on negatively charged cell surfaces. This unique structure enhanced membrane penetration, enabling superior delivery compared with linear and other cyclic variants. Y2-13-OX efficiently delivered functional siRNA targeting METTL3, achieving knockdown comparable to that of Lipofectamine 2000. It also transported GFP and plasmids, demonstrating versatility. Computational analysis revealed molecular-level insights into the enhanced interaction between the CC-loop structure and membranes. These findings establish a new CPP conformation that advances therapeutic delivery and opens new avenues for drug transport strategies.
- 29 October 2024
- Published by Wiley in Angewandte Chemie
- Vol. 136 (48)
Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma
METTL3 has emerged as a promising therapeutic target in cancer treatment, although its oncogenic functions in melanoma development and potential for therapeutic targeting drug have not been fully explored. In this study, we define the oncogenic role of METTL3 in melanoma development and progression. Building on this insight, we examine our recently designed peptide inhibitor RM3, which targets the binding interface of METTL3/14 complex for disruption and subsequent ubiquitin‐mediated proteasomal degradation via the E3 ligase STUB1. RM3 treatment reduces proliferation, migration, and invasion, and induces apoptosis in melanoma cells in vitro and in vivo. Subsequent transcriptomic analysis identified changes in immuno‐related genes following RM3‐mediated suppression of METTL3/14 N6‐methyladenosine (m6A) methyltransferase activity, suggesting a potential for interaction with immunotherapy. A combination treatment of RM3 with anti‐PD‐1 antibody results in significantly higher beneficial tumor response in vivo, with a good safety profile. Collectively, these findings not only delineate the oncogenic role of METTL3 in melanoma but also showcase RM3, acting as a peptide degrader, as a novel and promising strategy for melanoma treatment.
- 29 October 2024
- Published by Wiley in Angewandte Chemie
- Vol. 136 (48)
Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma
METTL3 has emerged as a promising therapeutic target in cancer treatment, although its oncogenic functions in melanoma development and potential for therapeutic targeting drug have not been fully explored. In this study, we define the oncogenic role of METTL3 in melanoma development and progression. Building on this insight, we examine our recently designed peptide inhibitor RM3, which targets the binding interface of METTL3/14 complex for disruption and subsequent ubiquitin‐mediated proteasomal degradation via the E3 ligase STUB1. RM3 treatment reduces proliferation, migration, and invasion, and induces apoptosis in melanoma cells in vitro and in vivo. Subsequent transcriptomic analysis identified changes in immuno‐related genes following RM3‐mediated suppression of METTL3/14 N6‐methyladenosine (m6A) methyltransferase activity, suggesting a potential for interaction with immunotherapy. A combination treatment of RM3 with anti‐PD‐1 antibody results in significantly higher beneficial tumor response in vivo, with a good safety profile. Collectively, these findings not only delineate the oncogenic role of METTL3 in melanoma but also showcase RM3, acting as a peptide degrader, as a novel and promising strategy for melanoma treatment.